Back to Search
Start Over
Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial
- Source :
- The Breast : official journal of the European Society of Mastology, Breast, Vol 53, Iss, Pp 1-7 (2020)
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Background Although randomized controlled clinical trials are optimal to evaluate the effect of an experimental therapy, single-arm trials are required whenever randomization is unethical or not feasible, such as de-escalation studies. We propose using prospectively identified historical controls to place results of single-arm, de-escalation trials into context. Methods POSITIVE is a prospective, single-arm study in young women with hormone-receptor-positive early breast cancer to determine if temporarily interrupting adjuvant endocrine therapy in order to become pregnant increases the risk of a breast cancer event. After 272 women enrolled in POSITIVE, we identified a cohort of 1499 SOFT/TEXT patients potentially eligible to enroll in POSITIVE who did not interrupt endocrine therapy. Method I used the SOFT/TEXT cohort to calculate annualized hazard rates by a piecewise exponential model. Method II used the SOFT/TEXT cohort to group-match SOFT/TEXT patients to POSITIVE patients; sample sets of SOFT/TEXT patients were randomly drawn 5000 times to obtain sets having patient, disease, and treatment characteristics more balanced with POSITIVE participants. Results Compared with SOFT/TEXT, POSITIVE participants were younger, less likely to be overweight/obese, had fewer positive nodes, and fewer received aromatase inhibitor or chemotherapy. The estimated 3-year breast cancer free interval event rates were 9.5% (95% CI: 7.9%,11.1%) for Method I and 9.4% (95% CI: 7.8%,10.9%) for Method II, compared with 5.8% initially assumed when POSITIVE was designed. Conclusion External control datasets should be identified before launching single-arm, de-escalation trials and methods applied during their conduct to provide context for interim monitoring and interpretation of the final analysis.<br />Highlights • Prospective identification of external historical controls for single-arm studies. • Statistical methods for estimating historical control rates for single-arm studies. • Methods applied for interim monitoring and final analysis of the POSITIVE study.
- Subjects :
- Adult
medicine.medical_specialty
Randomization
Adolescent
Antineoplastic Agents, Hormonal
Non-Randomized Controlled Trials as Topic
Receptor, ErbB-2
medicine.drug_class
Breast Neoplasms
Context (language use)
Kaplan-Meier Estimate
Overweight
lcsh:RC254-282
Young Adult
03 medical and health sciences
0302 clinical medicine
Breast cancer
Pregnancy
Internal medicine
medicine
Humans
Prospective Studies
030212 general & internal medicine
Proportional Hazards Models
Randomized Controlled Trials as Topic
Aromatase inhibitor
business.industry
Historically Controlled Study
General Medicine
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Clinical trial
Withholding Treatment
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
Cohort
Female
Original Article
Surgery
medicine.symptom
business
De-escalation
Subjects
Details
- ISSN :
- 09609776
- Volume :
- 53
- Database :
- OpenAIRE
- Journal :
- The Breast
- Accession number :
- edsair.doi.dedup.....e50eab4ae742cafa9a45fe3e70b75d62